Corbus Pharmaceuticals (CRBP) Coverage Initiated by Analysts at Oppenheimer

Share on StockTwits

Oppenheimer started coverage on shares of Corbus Pharmaceuticals (NASDAQ:CRBP) in a research report sent to investors on Tuesday morning, Marketbeat reports. The brokerage issued an outperform rating and a $28.00 target price on the biopharmaceutical company’s stock. Oppenheimer also issued estimates for Corbus Pharmaceuticals’ Q1 2019 earnings at $0.17 EPS, Q2 2019 earnings at ($0.25) EPS, Q3 2019 earnings at ($0.25) EPS, Q4 2019 earnings at ($0.24) EPS, FY2019 earnings at ($0.58) EPS, FY2020 earnings at ($1.02) EPS, FY2021 earnings at ($0.57) EPS and FY2022 earnings at $0.54 EPS.

CRBP has been the topic of a number of other research reports. ValuEngine downgraded shares of Corbus Pharmaceuticals from a strong-buy rating to a buy rating in a research note on Thursday, February 28th. Cantor Fitzgerald reaffirmed a buy rating and set a $38.00 price target on shares of Corbus Pharmaceuticals in a research note on Tuesday, March 12th. HC Wainwright reaffirmed a buy rating and set a $24.00 price target on shares of Corbus Pharmaceuticals in a research note on Friday, January 4th. Royal Bank of Canada assumed coverage on shares of Corbus Pharmaceuticals in a research note on Friday, December 7th. They set an outperform rating and a $23.00 price target on the stock. Finally, Zacks Investment Research downgraded shares of Corbus Pharmaceuticals from a strong-buy rating to a hold rating in a research note on Wednesday, March 13th. One research analyst has rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company’s stock. Corbus Pharmaceuticals presently has a consensus rating of Buy and an average target price of $24.50.

Corbus Pharmaceuticals stock opened at $7.05 on Tuesday. Corbus Pharmaceuticals has a 52-week low of $4.50 and a 52-week high of $9.11.

Corbus Pharmaceuticals (NASDAQ:CRBP) last released its quarterly earnings results on Tuesday, March 12th. The biopharmaceutical company reported ($0.30) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.23) by ($0.07). The business had revenue of $1.93 million for the quarter, compared to analysts’ expectations of $1.99 million. Corbus Pharmaceuticals had a negative net margin of 1,154.52% and a negative return on equity of 116.34%. Research analysts forecast that Corbus Pharmaceuticals will post -0.85 earnings per share for the current year.

In other news, insider Barbara White acquired 4,638 shares of the business’s stock in a transaction on Thursday, March 14th. The shares were acquired at an average price of $6.47 per share, for a total transaction of $30,007.86. Following the completion of the transaction, the insider now directly owns 184,159 shares of the company’s stock, valued at approximately $1,191,508.73. The acquisition was disclosed in a legal filing with the SEC, which is available through this hyperlink. Insiders have acquired 8,668 shares of company stock worth $56,923 in the last quarter. Company insiders own 12.60% of the company’s stock.

A number of hedge funds have recently bought and sold shares of the business. Bank of America Corp DE increased its position in Corbus Pharmaceuticals by 6.7% during the fourth quarter. Bank of America Corp DE now owns 37,304 shares of the biopharmaceutical company’s stock valued at $218,000 after acquiring an additional 2,335 shares during the last quarter. Barclays PLC increased its position in Corbus Pharmaceuticals by 5,967.8% during the fourth quarter. Barclays PLC now owns 9,041 shares of the biopharmaceutical company’s stock valued at $52,000 after acquiring an additional 8,892 shares during the last quarter. Vanguard Group Inc. increased its position in Corbus Pharmaceuticals by 0.5% during the third quarter. Vanguard Group Inc. now owns 2,390,014 shares of the biopharmaceutical company’s stock valued at $18,045,000 after acquiring an additional 11,609 shares during the last quarter. Vanguard Group Inc increased its position in Corbus Pharmaceuticals by 0.5% during the third quarter. Vanguard Group Inc now owns 2,390,014 shares of the biopharmaceutical company’s stock valued at $18,045,000 after acquiring an additional 11,609 shares during the last quarter. Finally, Cambridge Investment Research Advisors Inc. increased its position in Corbus Pharmaceuticals by 32.5% during the fourth quarter. Cambridge Investment Research Advisors Inc. now owns 47,534 shares of the biopharmaceutical company’s stock valued at $278,000 after acquiring an additional 11,650 shares during the last quarter. Institutional investors and hedge funds own 40.27% of the company’s stock.

About Corbus Pharmaceuticals

Corbus Pharmaceuticals Holdings, Inc, a clinical-stage pharmaceutical company, focuses on the development and commercialization of various therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. Its lead product candidate is lenabasum, a synthetic oral endocannabinoid-mimetic drug to resolve chronic inflammation and fibrotic processes in systemic sclerosis, cystic fibrosis, dermatomyositis, and systemic lupus erythematosus diseases.

Recommended Story: Straddles

Analyst Recommendations for Corbus Pharmaceuticals (NASDAQ:CRBP)

Receive News & Ratings for Corbus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corbus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Zacks Investment Research Upgrades NIO  to Hold
Zacks Investment Research Upgrades NIO to Hold
Oppenheimer Boosts CarMax  Price Target to $100.00
Oppenheimer Boosts CarMax Price Target to $100.00
Methode Electronics  Stock Rating Lowered by Zacks Investment Research
Methode Electronics Stock Rating Lowered by Zacks Investment Research
BidaskClub Downgrades InterDigital Wireless  to Strong Sell
BidaskClub Downgrades InterDigital Wireless to Strong Sell
Sesen Bio  Cut to Sell at Zacks Investment Research
Sesen Bio Cut to Sell at Zacks Investment Research
Park National  Upgraded to Hold at Zacks Investment Research
Park National Upgraded to Hold at Zacks Investment Research


© 2006-2019 Ticker Report